Drug intelligence / Profile preview

EG103

Development stage: Preclinical
Lead developer: Elisigen
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Ophthalmic

Overview

EG103 is an investigational adeno-associated virus (AAV)-based gene therapy being developed by Elisigen for the treatment of dry age-related macular degeneration (dry AMD), specifically geographic atrophy (GA). Currently in the preclinical stage, EG103 is designed to provide long-term therapeutic benefit through a single ocular administration, aiming to slow the progression of retinal degeneration. While the specific molecular target has not been disclosed, the program leverages Elisigen's expertise in ophthalmic gene delivery to address the significant unmet need in patients with advanced dry AMD.

Beyond the preview

Go deeper on EG103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EG103.

Explore the full profile